Douglas Strathdee

Tracking CDK1 Dynamics With a Novel Biosensor Mouse and Clinical Cohorts to Predict CDK4/6 Inhibitor Sensitivity in ER+ Breast Cancer

ABSTRACT High‐risk estrogen receptor positive (ER+) early breast cancer (EBC) is managed with endocrine therapies and cyclin‐dependent kinase (CDK) 4/6 inhibitors, although no standard molecular markers clinically identify these tumors. CDK1 lies immediately downstream of CDK4/6...